SARS-CoV-2 Infections in Patients Enrolled on the Children's Oncology Group Standard-risk B-cell Acute Lymphoblastic Leukemia Trial, AALL1731

Overview

Journal EJHaem

Specialty Hematology

Date 2023 Aug 21

PMID 37601850

Authors

Caitlin W Elgarten

John A Kairalla

Joel C Thompson

Tamara P Miller

Cindy Wang

Susan Conway

Mignon L Loh

Elizabeth A Raetz

Sumit Gupta

Rachel E Rau

Anne Angiolillo

Karen R Rabin

Sarah Alexander

Affiliations

Soon will be listed here.

Abstract

Hematologic malignancy is a risk factor for severe coronavirus disease 2019 (COVID-19) in adults; however, data specific to children with leukemia are limited. High-quality infectious adverse event data from the ongoing Children's Oncology Group (COG) standard-risk B acute lymphoblastic leukemia/lymphoma (ALL/LLy) trial, AALL1731, were analyzed to provide a disease-specific estimate of SARS-CoV-2 infection outcomes in pediatric ALL. Of 253 patients with reported infections, the majority (77.1%) were asymptomatic or mildly symptomatic (CTCAE grade 1/2) and there was a single COVID-19-related death. These data suggest SARS-CoV-2 infection does not confer substantial morbidity among young patients with B-lymphoblastic leukemia/lymphoma (B-ALL/LLy).

Citing Articles

COVID-19 in Pediatric Patients With Acute Lymphoblastic Leukemia or Lymphoma.

Hashmi S, Bodea J, Patni T, Angel S, Bhakta N, Jeha S JAMA Netw Open. 2024; 7(2):e2355727.

PMID: 38363571 PMC: 10873761. DOI: 10.1001/jamanetworkopen.2023.55727.

SARS-CoV-2 infections in patients enrolled on the Children's Oncology Group standard-risk B-cell acute lymphoblastic leukemia trial, AALL1731.

Elgarten C, Kairalla J, Thompson J, Miller T, Wang C, Conway S EJHaem. 2023; 4(3):745-750.

PMID: 37601850 PMC: 10435702. DOI: 10.1002/jha2.697.

References

Wiersinga W, Rhodes A, Cheng A, Peacock S, Prescott H . Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020; 324(8):782-793. DOI: 10.1001/jama.2020.12839. View

Wood W, Neuberg D, Thompson J, Tallman M, Sekeres M, Sehn L . Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub. Blood Adv. 2020; 4(23):5966-5975. PMC: 7724912. DOI: 10.1182/bloodadvances.2020003170. View

Boulad F, Kamboj M, Bouvier N, Mauguen A, Kung A . COVID-19 in Children With Cancer in New York City. JAMA Oncol. 2020; 6(9):1459-1460. PMC: 7221844. DOI: 10.1001/jamaoncol.2020.2028. View

Andre N, Rouger-Gaudichon J, Brethon B, Phulpin A, Thebault E, Pertuisel S . COVID-19 in pediatric oncology from French pediatric oncology and hematology centers: High risk of severe forms?. Pediatr Blood Cancer. 2020; 67(7):e28392. PMC: 7235489. DOI: 10.1002/pbc.28392. View

Madhusoodhan P, Pierro J, Musante J, Kothari P, Gampel B, Appel B . Characterization of COVID-19 disease in pediatric oncology patients: The New York-New Jersey regional experience. Pediatr Blood Cancer. 2020; 68(3):e28843. PMC: 7883045. DOI: 10.1002/pbc.28843. View

Emes D, Huls A, Baumer N, Dierssen M, Puri S, Russell L . COVID-19 in Children with Down Syndrome: Data from the Trisomy 21 Research Society Survey. J Clin Med. 2021; 10(21). PMC: 8584980. DOI: 10.3390/jcm10215125. View

Johnston E, Martinez I, Davis E, Caudill C, Richman J, Brackett J . SARS-CoV-2 in Childhood Cancer in 2020: A Disease of Disparities. J Clin Oncol. 2021; 39(34):3778-3788. PMC: 8608263. DOI: 10.1200/JCO.21.00702. View

Rouger-Gaudichon J, Bertrand Y, Boissel N, Brethon B, Ducassou S, Gandemer V . COVID19 and acute lymphoblastic leukemias of children and adolescents: Updated recommendations (Version 2) of the Leukemia Committee of the French Society for the fight against Cancers and leukemias in children and adolescents (SFCE). Bull Cancer. 2021; 108(5):490-500. PMC: 7951944. DOI: 10.1016/j.bulcan.2021.02.004. View

Elgarten C, Thompson J, Angiolillo A, Chen Z, Conway S, Devidas M . Improving infectious adverse event reporting for children and adolescents enrolled in clinical trials for acute lymphoblastic leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2022; 69(11):e29937. PMC: 9529813. DOI: 10.1002/pbc.29937. View

10.

Suzuki R, Yamasoba D, Kimura I, Wang L, Kishimoto M, Ito J . Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant. Nature. 2022; 603(7902):700-705. PMC: 8942852. DOI: 10.1038/s41586-022-04462-1. View

11.

Elgarten C, Kairalla J, Thompson J, Miller T, Wang C, Conway S . SARS-CoV-2 infections in patients enrolled on the Children's Oncology Group standard-risk B-cell acute lymphoblastic leukemia trial, AALL1731. EJHaem. 2023; 4(3):745-750. PMC: 10435702. DOI: 10.1002/jha2.697. View

12.

Sullivan M, Bouffet E, Rodriguez-Galindo C, Luna-Fineman S, Khan M, Kearns P . The COVID-19 pandemic: A rapid global response for children with cancer from SIOP, COG, SIOP-E, SIOP-PODC, IPSO, PROS, CCI, and St Jude Global. Pediatr Blood Cancer. 2020; 67(7):e28409. PMC: 7235469. DOI: 10.1002/pbc.28409. View

13.

He W, Chen L, Chen L, Yuan G, Fang Y, Chen W . COVID-19 in persons with haematological cancers. Leukemia. 2020; 34(6):1637-1645. PMC: 7180672. DOI: 10.1038/s41375-020-0836-7. View

14.

Mukkada S, Bhakta N, Chantada G, Chen Y, Vedaraju Y, Faughnan L . Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study. Lancet Oncol. 2021; 22(10):1416-1426. PMC: 8389979. DOI: 10.1016/S1470-2045(21)00454-X. View

15.

Pagano L, Salmanton-Garcia J, Marchesi F, Busca A, Corradini P, Hoenigl M . COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). J Hematol Oncol. 2021; 14(1):168. PMC: 8515781. DOI: 10.1186/s13045-021-01177-0. View

16.

Wang H, Zhang L . Risk of COVID-19 for patients with cancer. Lancet Oncol. 2020; 21(4):e181. PMC: 7129735. DOI: 10.1016/S1470-2045(20)30149-2. View

17.

Faulk K, Anderson-Mellies A, Cockburn M, Green A . Assessment of enrollment characteristics for Children's Oncology Group (COG) upfront therapeutic clinical trials 2004-2015. PLoS One. 2020; 15(4):e0230824. PMC: 7179840. DOI: 10.1371/journal.pone.0230824. View